Abstract: A control method of a driving mechanism is provided, including: the driving mechanism provides a first electrical signal from a control assembly to the driving mechanism to move the movable portion into an initial position relative to the fixed portion, wherein the control assembly includes a control unit and a position sensing unit; the status signal of an inertia sensing unit is read; the control unit sends the status signal to the control unit to calculate a target position; the control unit provides a second electrical signal to the driving assembly according to the target position for driving the driving assembly; a position signal is sent from the position sensing unit to the control unit; the control unit provides a third electric signal to the driving assembly to drive the driving assembly according the position signal.

Abstract: Melanogenesis-inhibitory constituents of Ligusticum sinense are disclosed. The melanogenesis-inhibitory constituents can be compound I, II, or III having the chemical structures as follow, respectively.

Abstract: This invention relates to a novel compound extracted from antrodia Cinnamomea and related compounds of formula (1), and pharmaceutical compositions comprising the compound of formula (1) and a pharmaceutically acceptable carrier or excipient. The invention further comprises the method of inhibit cancer cells by administering an effective amount of the compound of formula (1).

Abstract: Compounds extracted from Rhodiola rosea have ability to inhibit gelatinases and collagenases activity. The compounds have the chemical structure as shown below.

Abstract: The present invention relates to compounds of formual (I): wherein Y is a single bond or double bound; and R1 is —C(CH3)C2H5 or —C(CH3)?CHCH3, when Y is a single bound; R1 is —C(CH3)?CH2, is —C(CH3)2, —C(CH3)?CHCH3, —C(CH3)C2H5, or —CH2C(CH3)2, when Y is a double bound. These compounds are bombesin receptor subtype 3 (BRS3) modulating agents, more specifically that they are BRS3 agonists. The invention is also related to the use of such compounds to treat diseases associated with inappropriate BRS3 activity.

Abstract: This invention relates to a novel compound extracted from antrodia Cinnamomea and related compounds of formula (1), and pharmaceutical compositions comprising the compound of formula (1) and a pharmaceutically acceptable carrier or excipient. The invention further comprises the method of inhibit cancer cells by administering an effective amount of the compound of formula (1).

Abstract: Compounds extracted from Rhodiola rosea have ability to inhibit gelatinases and collagenases activity. The compounds have the chemical structure as shown below.